

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Sponsored Subaward Agreement between the University of Michigan and Imbio, LLC

Action Requested: Authorization to enter into a Subaward Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Contract Administration while reviewing the request to issue a sponsored subaward.

This proposed Research Subaward Agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Drs. Brian Ross and Alnawaz Rehemtulla are employees of the University of Michigan (“University”) and have an equity interest in Imbio, LLC (“Imbio”).

The law permits such an Agreement provided it is disclosed to the Board of Regents of the University and approved in advance by a 2/3 vote.

Background:

The University Of Michigan School of Medicine, through its Department of Radiology, seeks approval to enter into an Agreement with Imbio to collaborate in support of the Project entitled “Advancing Quantification of Diffusion MRI for Oncologic Imaging”, funded by National Cancer Institute Grant No. U01CA166104 (PAF# 15-PAF02832). The purpose of the Project is to advance the use of image analysis of diffusion-weighted magnetic resonance images (DW-MRI) as an early image-based biomarker of treatment response in patients with primary breast cancer undergoing neoadjuvant therapy.

The proposed Agreement will fund Imbio to collaborate with the University to design and implement a software prototype which will be capable of providing a semi-automated analysis of breast cancer diffusion-weighted MRI scans.

Agreement Terms:

The terms of the proposed Agreement will conform to University policy. The total period of performance for the project is September 22, 2015 through August 31, 2020. The amount of funding support is expected not exceed \$781,736.00. Since research projects are often amended, the Agreement will include a provision for changes in time, amount, and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement

Imbio has exclusively licensed the patented University technology related to the use of diffusion-weighted MRI for cancer treatment response detection. The Agreement will provide the collaboration necessary for the University to carry out its obligations under its Prime Award.

Recommendations:

The Medical School Conflict of Interest Board has reviewed this matter and determined that a formal management plan is required and will be implemented for Dr. Brian Ross. In light of this determination and our finding that the Agreement will be negotiated in conformance with standard University practices, I recommend that the Board of Regents approve of the University entering into this Agreement with Imbio.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kevin P. Hegarty", with several loops and a long horizontal stroke extending to the right.

Kevin P. Hegarty
Executive Vice President and Chief Financial Officer

June 2016